Yunlong Cui

1.5k total citations
52 papers, 1.1k citations indexed

About

Yunlong Cui is a scholar working on Hepatology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Yunlong Cui has authored 52 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hepatology, 18 papers in Pulmonary and Respiratory Medicine and 15 papers in Oncology. Recurrent topics in Yunlong Cui's work include Hepatocellular Carcinoma Treatment and Prognosis (20 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers) and Cancer Mechanisms and Therapy (7 papers). Yunlong Cui is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (20 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers) and Cancer Mechanisms and Therapy (7 papers). Yunlong Cui collaborates with scholars based in China, United States and Ethiopia. Yunlong Cui's co-authors include Ti Zhang, Huikai Li, Tianqiang Song, Hongyuan Zhou, Qiang Wu, Fang Fěng, Wei Zhang, Xishan Hao, Tianqiang Song and Lisha Qi and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Yunlong Cui

51 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yunlong Cui China 18 462 346 297 287 262 52 1.1k
Hengjun Gao China 18 399 0.9× 344 1.0× 193 0.6× 253 0.9× 171 0.7× 50 931
Jiayin Yang China 17 311 0.7× 261 0.8× 195 0.7× 287 1.0× 200 0.8× 68 861
Chengjun Sui China 23 679 1.5× 625 1.8× 362 1.2× 495 1.7× 449 1.7× 58 1.5k
Xiang Xiao China 14 365 0.8× 245 0.7× 239 0.8× 410 1.4× 185 0.7× 29 1.1k
Yajin Chen China 15 550 1.2× 340 1.0× 195 0.7× 235 0.8× 127 0.5× 43 959
Xiaoping Geng China 17 320 0.7× 181 0.5× 159 0.5× 205 0.7× 246 0.9× 81 886
Xiaoqing Jiang China 18 663 1.4× 484 1.4× 176 0.6× 239 0.8× 245 0.9× 33 1.1k
Xueshuai Wan China 19 421 0.9× 365 1.1× 96 0.3× 356 1.2× 280 1.1× 50 1.1k
Jiliang Shen China 13 644 1.4× 353 1.0× 149 0.5× 259 0.9× 120 0.5× 29 1.1k

Countries citing papers authored by Yunlong Cui

Since Specialization
Citations

This map shows the geographic impact of Yunlong Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yunlong Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yunlong Cui more than expected).

Fields of papers citing papers by Yunlong Cui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yunlong Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yunlong Cui. The network helps show where Yunlong Cui may publish in the future.

Co-authorship network of co-authors of Yunlong Cui

This figure shows the co-authorship network connecting the top 25 collaborators of Yunlong Cui. A scholar is included among the top collaborators of Yunlong Cui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yunlong Cui. Yunlong Cui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Yang, Yayue Liu, Linlin Fu, et al.. (2024). Durvalumab plus gemcitabine/cisplatin/nab-paclitaxel in resectable biliary tract cancer: A phase II, single-arm, open-label study (DurGAP).. Journal of Clinical Oncology. 42(16_suppl). e16260–e16260. 1 indexed citations
2.
3.
Jiang, Ning, et al.. (2023). Hepatic Runx1t1 improves body fat index after endurance exercise in obese mice. Scientific Reports. 13(1). 19427–19427. 1 indexed citations
4.
Liu, K., Yunlong Cui, Hua Li, et al.. (2023). The mechanism investigation of mutation genes in liver and lung metastasis of colorectal cancer by using NGS technique. Critical Reviews in Oncology/Hematology. 188. 104057–104057. 2 indexed citations
5.
6.
Cui, Yunlong & Ning Jiang. (2023). CDCA8 Facilitates Tumor Proliferation and Predicts a Poor Prognosis in Hepatocellular Carcinoma. Applied Biochemistry and Biotechnology. 196(3). 1481–1492. 9 indexed citations
7.
Cui, Yunlong, Hua Li, Tao Han, et al.. (2021). Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics. Frontiers in Oncology. 11. 733478–733478. 4 indexed citations
8.
Zhou, Hongyuan, Feng Fang, Yunlong Cui, et al.. (2021). MicroRNA-361 suppresses the biological processes of hepatic stellate cells in HBV-relative hepatic fibrosis by NF-kappaB p65. PubMed. 167. 203711–203711. 2 indexed citations
9.
Yang, Xuejiao, Zhenyu Hou, Keyun Zhu, et al.. (2020). <p>Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma</p>. Cancer Management and Research. Volume 12. 3163–3173. 9 indexed citations
10.
Hou, Zhenyu, Keyun Zhu, Xuejiao Yang, et al.. (2020). Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial. Annals of Translational Medicine. 8(17). 1047–1047. 26 indexed citations
11.
Chen, Lu, Yuchao He, Ziye Chen, et al.. (2018). HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway. Cell Death and Disease. 9(5). 513–513. 192 indexed citations
12.
Sun, Lin, Manqing Cao, Hongyuan Zhou, et al.. (2017). Decreased expression of acetyl‐CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma. Cancer Science. 108(7). 1338–1346. 41 indexed citations
13.
Wang, Yu, Sinan Wang, Hongyuan Zhou, et al.. (2016). Acinar cell carcinoma: a report of 19 cases with a brief review of the literature. World Journal of Surgical Oncology. 14(1). 172–172. 44 indexed citations
14.
You, A‐Bin, Manqing Cao, Bingfeng Zuo, et al.. (2016). Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. Journal of Hematology & Oncology. 9(1). 20–20. 57 indexed citations
15.
Zhu, Xiaolin, Hongyuan Zhou, Yunlong Cui, et al.. (2016). Different but synergistic effects of bone marrow-derived VEGFR2+ and VEGFR2−CD45+ cells during hepatocellular carcinoma progression. Oncology Letters. 13(1). 63–68. 3 indexed citations
16.
Zhang, Haiqiang, et al.. (2009). Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats. World Journal of Gastroenterology. 15(15). 1821–1821. 47 indexed citations
17.
Li, Qiang, Jian Wang, Yan Sun, et al.. (2008). Clonality Analysis for Multicentric Origin and Intrahepatic Metastasis in Recurrent and Primary Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery. 12(9). 1540–1547. 42 indexed citations
18.
Wang, Jian, Yan Sun, Hong Zheng, et al.. (2008). Clinicopathologic features between multicentric occurence and intrahepatic metastasis of multiple hepatocellular carcinomas related to HBV. Surgical Oncology. 18(1). 25–30. 27 indexed citations
19.
Li, Qiang, Jian Wang, Yan Sun, Yunlong Cui, & Xishan Hao. (2007). Hepatic angiosarcoma arising in an adult mesenchymal hamartoma. PubMed. 4(1). 3–3. 13 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hengjun Gao Breakdown of academic impact, for papers by Jiayin Yang Breakdown of academic impact, for papers by Chengjun Sui Breakdown of academic impact, for papers by Xiang Xiao Breakdown of academic impact, for papers by Yajin Chen Breakdown of academic impact, for papers by Xiaoping Geng Breakdown of academic impact, for papers by Xiaoqing Jiang Breakdown of academic impact, for papers by Xueshuai Wan Breakdown of academic impact, for papers by Jiliang Shen
Rankless by CCL
2026